Sharing the Latest Therapeutic Strategies for IBD

Samsung Bioepis announced on January 27 that it held a symposium titled 'SYMBOL 2026' on January 24 and 25 at the Westin Seoul Parnas Hotel in Gangnam-gu, Seoul, targeting domestic gastroenterology specialists to share the latest research and clinical trends in the treatment of inflammatory bowel disease (IBD).


This symposium was organized to address the rapidly changing treatment landscape of inflammatory bowel diseases such as Crohn's disease and ulcerative colitis and to discuss the latest therapeutic strategies. More than 70 domestic gastroenterology healthcare professionals attended, engaging in discussions on topics such as patient treatment and management strategies, the latest treatment guidelines, and real-world application methods based on clinical cases.

Samsung Bioepis held a symposium titled 'SYMBOL 2026' on the 24th and 25th at the Westin Seoul Parnas Hotel in Gangnam-gu, Seoul, targeting domestic gastroenterology specialists to share the latest research and clinical trends in the treatment of inflammatory bowel disease (IBD). The photo shows the symposium venue. Photo by Samsung Bioepis

Samsung Bioepis held a symposium titled 'SYMBOL 2026' on the 24th and 25th at the Westin Seoul Parnas Hotel in Gangnam-gu, Seoul, targeting domestic gastroenterology specialists to share the latest research and clinical trends in the treatment of inflammatory bowel disease (IBD). The photo shows the symposium venue. Photo by Samsung Bioepis

View original image

At the symposium, Samsung Bioepis also introduced its biosimilar product 'Epizetec' (ingredient: ustekinumab), which can be used in the treatment of inflammatory bowel disease. Epizetec is a biosimilar to Stelara and is used for the treatment of autoimmune diseases such as plaque psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis by inhibiting the activity of the immune-related neurotransmitters interleukin (IL)-12 and IL-23.


Samsung Bioepis obtained the first domestic approval for the Stelara biosimilar Epizetec in April 2024 and launched it in July of the same year at a price approximately 40% lower than the original Stelara. On January 13, Epizetec became the first ustekinumab-based product sold in Korea to receive additional approval for a pre-filled pen (PFP) formulation.



Jung Jinhan, Executive Director at Samsung Bioepis, said, "We will continue to strive to provide optimal treatment options for patients through ongoing academic communication with healthcare professionals in the field."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing